The Highly Evolvable Antibody Fc Domain

Trends in Biotechnology

Volumn 34, Issue 11, 2016, Pages 895-908

  Park, Hye In ^a   Yoon, Hyun Woung ^a   Jung, Sang Taek ^a  

^a Kookmin University   (South Korea)

Author keywords

antibody engineering; antibody Fc; effector functions; serum half life

Indexed keywords

ANTIGENS; BINS; BODY FLUIDS; DIAGNOSIS;

ANTIBODY ENGINEERING; ANTIBODY THERAPEUTICS; EVOLUTIONARY APPROACH; HALF LIVES; HIGH THROUGHPUT SCREENING; INTRACELLULAR TRAFFICKING; PROLONGED SERUM HALF-LIFE; THERAPEUTIC ANTIBODIES;

ANTIBODIES;

COMPLEMENT COMPONENT C1Q; FC RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN;

ADAPTIVE IMMUNITY; ANTIGEN BINDING; BINDING AFFINITY; CELL MIGRATION; COMPLEMENT DEPENDENT CYTOTOXICITY; HUMAN; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; REVIEW; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MICE; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

EID: 84965102123     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2016.04.005     Document Type: Review

References (71)

1. 1 Walsh, G., Biopharmaceutical benchmarks 2014. Nat. Biotech. 32 (2014), 992–1000.
2. 2 Rosati, S., et al. In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap. mAbs 5 (2013), 917–924.
3. 3 Subedi, G.P., Barb, A.W., The structural role of antibody N-glycosylation in receptor interactions. Structure 23 (2015), 1573–1583.
4. 4 Jefferis, R., Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 8 (2009), 226–234.
5. 5 Niwa, R., Satoh, M., The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology. J. Pharm. Sci. 104 (2015), 930–941.
6. 6 Beck, A., Reichert, J.M., Marketing approval of mogamulizumab: a triumph for glyco-engineering. mAbs 4 (2012), 419–425.
7. 7 Cerquozzi, S., Owen, C., Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia. Biologics: Targets Ther. 9 (2015), 13–22.
8. 8 Ridgway, J.B.B., et al. ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9 (1996), 617–621.
9. 9 Ko, S., Jung, S., Engineering antibodies for dual specificity and enhanced potency. Biotechnol. Bioproc. E. 20 (2015), 201–210.
10. 10 Shatz, W., et al. Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. mAbs 5 (2013), 872–881.
11. 11 Pincetic, A., et al. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat. Immunol. 15 (2014), 707–716.
12. 12 Thomann, M., et al. In vitro glycoengineering of IgG1 and Its effect on Fc receptor binding and ADCC activity. PLoS ONE, 10, 2015, e0134949.
13. 13 Liu, R., et al. Evaluation of a glycoengineered monoclonal antibody via LC-MS analysis in combination with multiple enzymatic digestion. mAbs 8 (2016), 340–346.
14. 14 Lazar, G.A., et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. U.S.A. 103 (2006), 4005–4010.
15. 15 Jung, S.T., et al. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 604–609.
16. 16 Jung, S.T., et al. Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high Fc gamma RIIa affinity and selectivity. ACS Chem. Biol. 8 (2013), 368–375.
17. 17 Sazinsky, S.L., et al. Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 20167–20172.
18. 18 Stavenhagen, J.B., et al. Fc Optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion In vivo via low-affinity activating Fc gamma receptors. Cancer Res. 67 (2007), 8882–8890.
19. 19 Horton, H.M., et al. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood 116 (2010), 3004–3012.
20. 20 Horton, H.M., et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 68 (2008), 8049–8057.
21. 21 Mohseni Nodehi, S., et al. Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96. PLoS ONE, 7, 2012, e42426.
22. 22 Richards, J.O., et al. Optimization of antibody binding to Fc gamma RIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 7 (2008), 2517–2527.
23. 23 Nordstrom, J., et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fc gamma receptor binding properties. Breast Cancer Res., 13, 2011, R123.
24. 24 Loo, D., et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin. Cancer Res. 18 (2012), 3834–3845.
25. 25 Caaveiro, J.M.M., et al. Structural analysis of Fc/Fc gamma R complexes: a blueprint for antibody design. Immunol. Rev. 268 (2015), 201–221.
26. 26 Liu, Z., et al. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies. J. Biol. Chem. 289 (2014), 3571–3590.
27. 27 Chu, S.Y., et al. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and Fc gamma RIIb with Fc-engineered antibodies. Mol. Immunol. 45 (2008), 3926–3933.
28. 28 Mimoto, F., et al. Engineered antibody Fc variant with selectively enhanced Fc gamma RIIb binding over both Fc gamma RIIa(R131) and Fc gamma RIIa(H131). Protein Eng. Des. Sel. 26 (2013), 589–598.
29. 29 Kelton, W., et al. IgGA: a ‘cross-isotype’ engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions. Chem. Biol. 21 (2014), 1603–1609.
30. 30 Hristodorov, D., et al. Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies. Mol. Biotechnol. 53 (2013), 326–335.
31. 31 Ju, M-S., Jung, S.T., Aglycosylated full-length IgG antibodies: steps toward next-generation immunotherapeutics. Curr. Opin. Biotech. 30 (2014), 128–139.
32. 32 Jung, S., Kang, T.H., Engineering an aglycosylated Fc variant for enhanced Fc gamma RI engagement and pH-dependent human FcRn binding. Biotechnol. Bioproc. E. 19 (2014), 780–789.
33. 33 Borrok, M.J., et al. Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem. Biol. 7 (2012), 1596–1602.
34. 34 Jung, S.T., et al. Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy. Curr. Opin. Biotech. 22 (2011), 858–867.
35. 35 Ju, M-S., et al. Structural consequences of aglycosylated IgG Fc variants evolved for Fc gamma RI binding. Mol. Immunol. 67 (2015), 350–356.
36. 36 Idusogie, E.E., et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 164 (2000), 4178–4184.
37. 37 Hezareh, M., et al. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol. 75 (2001), 12161–12168.
38. 38 Idusogie, E.E., et al. Engineered antibodies with increased activity to recruit complement. J. Immunol. 166 (2001), 2571–2575.
39. 39 Natsume, A., et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res. 68 (2008), 3863–3872.
40. 40 Moore, G.L., et al. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. mAbs 2 (2010), 181–189.
41. 41 Grevys, A., et al. Fc engineering of human IgG1 for altered binding to the neonatal Fc receptor affects Fc effector functions. J. Immunol. 194 (2015), 5497–5508.
42. 42 Shields, R.L., et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276 (2001), 6591–6604.
43. 43 Hinton, P.R., et al. An engineered human IgG1 antibody with longer serum half-Life. J. Immunol. 176 (2006), 346–356.
44. 44 Stapleton, N.M., et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat. Commun., 2, 2011, 599.
45. 45 Dall'Acqua, W.F., et al. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 281 (2006), 23514–23524.
46. 46 Robbie, G.J., et al. A novel investigational Fc-modified humanized monoclonal antibody, Motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob. Agents Chemother 57 (2013), 6147–6153.
47. 47 Yeung, Y.A., et al. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J. Immunol. 182 (2009), 7663–7671.
48. 48 Borrok, M.J., et al. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. J. Biol. Chem. 290 (2015), 4282–4290.
49. 49 Zalevsky, J., et al. Enhanced antibody half-life improves in vivo activity. Nat. Biotech. 28 (2010), 157–159.
50. 50 Wozniak-Knopp, G., et al. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng. Des. Sel. 23 (2010), 289–297.
51. 51 Traxlmayr, M.W., et al. Directed evolution of stabilized IgG1-Fc scaffolds by application of strong heat shock to libraries displayed on yeast. B.B.A. Proteins Proteom. 1824 (2012), 542–549.
52. 52 Wozniak-Knopp, G., et al. Stabilisation of the Fc fragment of human IgG1 by engineered intradomain disulfide bonds. PLoS ONE, 7, 2012, e30083.
53. 53 Jensen, P.F., et al. Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry. Mol. Cell. Proteomics 14 (2015), 148–161.
54. 54 DiLillo, et al. Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell 161 (2015), 1035–1045.
55. 55 Pridgen, E.M., et al. Transepithelial transport of Fc -targeted nanoparticles by the neonatal Fc receptor for oral delivery. Sci. Transl. Med., 5, 2013 213ra167-213.
56. 56 Foss, S., et al. Enhanced FcRn-dependent transepithelial delivery of IgG by Fc engineering and polymerization. J. Control Release 223 (2016), 42–52.
57. 57 Levin, D., et al. Fc fusion as a platform technology: potential for modulating immunogenicity. Trends Biotechnol. 33 (2015), 27–34.
58. 58 Guilliams, M., et al. The function of Fc gamma receptors in dendritic cells and macrophages. Nat. Rev. Immunol. 14 (2014), 94–108.
59. 59 Bruhns, P., et al. Specificity and affinity of human Fc gamma receptors and their polymorphic variants for human IgG subclasses. Blood 113 (2009), 3716–3725.
60. 60 Gillis, C.M., et al. Contribution of human Fc gamma Rs to disease with evidence from human polymorphisms and transgenic animal studies. Front. Immunol., 5, 2014, 234.
61. 61 Yee, A.M.F., et al. Association between Fc gamma RIIa-R131 allotype and bacteremic Pneumococcal pneumonia. Clin. Infect. Dis. 30 (2000), 25–28.
62. 62 Shashidharamurthy, R., et al. Dynamics of the interaction of human IgG subtype immune complexes with cells expressing R and H allelic forms of a low-affinity Fc gamma receptor CD32A. J. Immunol. 183 (2009), 8216–8224.
63. 63 Khor, C.C., et al. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat. Genet. 43 (2011), 1241–1246.
64. 64 Tamura, K., et al. FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann. Oncol. 22 (2011), 1302–1307.
65. 65 Cooper, N., et al. Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia. Brit. J. Haematol. 158 (2012), 539–547.
66. 66 Moroi, R., et al. FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity. Immunogenetics 65 (2013), 265–271.
67. 67 Diebolder, C.A., et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 343 (2014), 1260–1263.
68. 68 Marina, S., et al. Structural basis of complement membrane attack complex formation. Nat. Commun., 7, 2016, 10587.
69. 69 Godau, J., et al. C5a initiates the inflammatory cascade in immune complex peritonitis. J. Immunol. 173 (2004), 3437–3445.
70. 70 Simmons, L.C., et al. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J. Immunol. Methods 263 (2002), 133–147.
71. 71 Sockolosky, J.T., et al. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv. Drug Deliv. Rev. 91 (2015), 109–124.